26 active trials 23 recruiting 7 Phase 3 18 disease areas 5 changes in 30 days
1 trial changed in the last 30 days: 0 stopped, 1 with a notable change, 0 with minor changes only.
Primary completion pushed from Dec 2025 to Jun 30, 2027
Also in this update: Primary endpoint(s) modified; Enrollment increased: 285 → 333 participants
Ascentage Pharma Group Inc.Phase 3 NCT06423911 Registry history of NCT06423911 on ClinicalTrials.gov (opens the registry)
Updated
| Phase 1 | 11 | |
| Phase 1/2 | 6 | |
| Phase 2 | 2 | |
| Phase 3 | 7 |
| NCT ID | Title | Condition | Status | Updated |
|---|---|---|---|---|
| Phase 3 | ||||
| NCT06423911 | Study of Olverembatinib (HQP1351) in Patients With CML-CP | Chronic Myeloid Leukemia | Recruiting | 2026-09-15 |
| NCT06319456 | A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy… | CLL/SLL | Recruiting | 2026-07-28 |
| NCT06640361 | A Study of Olverembatinib in SDH-deficient GIST. | GIST | Recruiting | 2026-07-23 |
| NCT06104566 | Global Trial in APG2575 for Patients With CLL/SLL | CLL/SLL | Recruiting | 2026-06-18 |
| NCT06051409 | A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1) | Ph+ ALL | Recruiting | 2026-04-30 |
| NCT06389292 | A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of… | Acute Myeloid Leukemia | Recruiting | 2025-11-25 |
| NCT06641414 | Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With… | Higher-risk Myelodysplastic Syndrome | Recruiting | 2025-11-20 |
| Phase 2 | ||||
| NCT05147467 | Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL | Chronic Lymphocytic Leukemia | Recruiting | 2026-03-27 |
| NCT04496349 | A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects… | T-Prolymphocytic Leukemia | Recruiting | 2025-11-04 |
| Phase 1/2 | ||||
| NCT05701306 | APG-115 Alone or in Combination With APG-2575 in Recurrent or Refractory Neuroblastoma or… | Neuroblastoma | Recruiting | 2026-08-21 |
| NCT04501120 | Study of Lisaftoclax (APG-2575) Single Agent and Combination With Therapy in Patients… | Relapsed/Refractory Acute Myeloid Leukaemia | Recruiting | 2026-04-29 |
| NCT06182969 | A Study of APG-2575 in Patients With Mild-to-moderate Systemic Lupus Erythematosus. | SLE | Recruiting | 2025-12-16 |
| NCT04494503 | Study of APG2575 Single Agent and Combination Therapy in Patients With… | Chronic Lymphocytic Leukemia | Recruiting | 2025-04-16 |
| NCT04785196 | APG-115 in Combination With PD-1 Inhibitor in Patients With Advanced Liposarcoma or… | Liposarcoma | Recruiting | 2025-02-26 |
| NCT03611868 | A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With… | Unresectable or Metastatic Melanoma or Advanced Solid Tumors | Active, Not Recruiting | 2025-08-07 |
| Phase 1 | ||||
| NCT07424833 | A Study of APG-3288 in Relapsed/Refractory Blood Cancers | Relapsed/Refractory Hematological Malignancies | Recruiting | 2026-07-30 |
| NCT03917043 | APG-2449 in Patients With Advanced Solid Tumors | Advanced Solid Cancer | Recruiting | 2026-07-23 |
| NCT06687070 | APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant… | Platinum-resistant Recurrent Ovarian Cancer | Recruiting | 2026-07-21 |
| NCT05773586 | A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of APG-5918. | Anemia | Recruiting | 2026-04-15 |
| NCT03594422 | A Study of HQP1351 in Patients With GIST or Other Solid Tumors | Gastrointestinal Stromal Tumor (GIST) | Recruiting | 2026-04-09 |
| NCT07282093 | Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment | Pharmacokinetic | Recruiting | 2025-12-23 |
| NCT04260022 | Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL | Leukemia, Myeloid, Chronic | Recruiting | 2025-11-05 |
| NCT04215809 | Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for… | CLL/SLL | Recruiting | 2025-04-10 |
| NCT04275518 | A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine… | Acute Myeloid Leukemia (AML) | Recruiting | 2024-10-15 |
| NCT03913949 | A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic… | Chronic Lymphocytic Leukemia | Active, Not Recruiting | 2026-05-01 |
Leukemia (11) · Chronic Lymphocytic Leukemia (CLL) (7) · Acute Myeloid Leukemia (AML) (3) · Non-Hodgkin Lymphoma (3) · Acute Lymphoblastic Leukemia (ALL) (2) · Chronic Myeloid Leukemia (CML) (2) · Lung Cancer (2) · Myelodysplastic Syndromes (MDS) (2) · Non-Small Cell Lung Cancer (NSCLC) (2) · Ovarian Cancer (2)